Date of Defense



Biological Sciences

First Advisor

John Spitsbergen, Biological Sciences

Second Advisor

Thomas Thamann, Pharmacia and Upjohn


Delavirdine is a potential AIDS drug called a non-nucleoside reverse transcriptase inhibitor. There are seven components that make up this drug: delavirdine mesylate, croscarmellose sodium, microcrystalline cellulose, lactose, hydroxypropyl methylcellulose, cilicon, and magnesium stearate. Delavirdine has a low bioavailability and solubility once the drug is taken orally into the body. In this project, infrared spectra of the drug delavirdine showed chemical changes occurring within the tablet. Delavirdine mesylate is shown changing to delavirdine free base and croscarmellose sodium is shown changing to croscarmellose acid. Infrared spectral analysis of various mixtures of the changing components confirmed these chemical changes, but further studies should be conducted in this area for more accurate results. The author has provided experimental results showing that indeed delavirdine mesylate is changing to its free base and that croscarmellose sodium is changing to its acid, which indicates that these two components are the cause of this drug's low bioavailability and solubility in the body. Upon conclusion of this experiment, the necessary changes in drug composition can be made for future use in AIDS patients.

Access Setting

Honors Thesis-Campus Only